In-Ear EEG Wearable NeuroBuds Receives CE Mark for Home Monitoring

An in-ear EEG wearable that patients can apply themselves and wear for up to three months has received CE marking for the European market, clearing the way for multi-day and multi-night brain monitoring in patients' homes without a technician-applied electrode cap.

Cebreo Medical, the manufacturer, designed NeuroBuds to resemble a hearing aid. That form factor is deliberate: it minimizes the stigma and burden attached to conventional long-term EEG monitoring, which typically requires scalp electrodes applied by trained staff in a clinic or sleep laboratory.

The device supports monitoring periods of up to three months with repeat measurements. Clinicians can capture EEG continuously across days and nights while the patient goes about daily life, rather than during a brief laboratory admission or a single-night sleep study.

What does this change for reading rooms and monitoring units?

The practical shift is longitudinal data at scale. For sleep medicine, extended ambulatory EEG monitoring applies to diagnostic work that currently depends on polysomnography in a lab or short ambulatory recordings. For epilepsy, the stakes are higher.

"With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients' own homes," said Rasmus Madsen, PhD, CEO of Cebreo Medical, in a release. "The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring."

Cost is the operative word. Long-term video-EEG monitoring in an epilepsy monitoring unit consumes bed days and staffing; a wearable that runs for weeks in the patient's own environment removes both from the equation, according to the company.

Why seizure counting matters in drug-resistant epilepsy

For patients with drug-resistant epilepsy, treatment decisions hinge on an accurate longitudinal picture of seizure frequency and treatment response. Patient diaries are the weak link.

"For patients with drug-resistant epilepsy, the question is not whether they have seizures — it's how often, and whether a new treatment is actually working," said Sandor Beniczby — Sandor Beniczky, MD, PhD, professor at the department of clinical neurophysiology at Rigshospitalet and the Danish Epilepsy Centre, in a release. "Patient-reported seizure counts are often unreliable, particularly for subtle or nocturnal seizures patients don't even notice."

An ambulatory ear-EEG device running for weeks in the patient's daily life provides EEG data with the potential to objectively quantify seizure burden and evaluate treatment more properly, Beniczky said.

The clinical logic is straightforward. Nocturnal and subtle seizures escape patient awareness, so diaries systematically undercount. Continuous EEG over weeks offers an objective denominator that a two-week diary cannot match.

What remains investigational, and what comes next

CE marking authorizes commercialization in Europe; it is not FDA clearance. Cebreo Medical plans to expand commercial availability across European research and clinical sites while advancing its US regulatory pathway, so American readers should treat this as an investigational device for now.

The company also positions NeuroBuds for broader neurophysiological research beyond sleep and epilepsy, where longitudinal EEG datasets remain scarce because conventional systems cannot practically record for months at a time.

One caveat for readers: the claims around seizure-burden quantification rest on the potential of the recording method, as Beniczky framed it, rather than on published outcome data cited in the announcement. How in-ear electrode montages compare with full scalp EEG for ictal detection over multi-week horizons will be the question European centers answer first as deployment widens.

If the US pathway succeeds, home-based multi-week EEG could move from niche research tool to routine practice in epilepsy follow-up.